FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913335890> ?p ?o ?g. }

• W2913335890 endingPage "363" @default.
• W2913335890 startingPage "354" @default.
• W2913335890 abstract "Visual Abstract Export Background and objectives Imarikiren is a novel, potent, and selective direct renin inhibitor that has shown high oral availability during clinical development for the treatment of diabetic nephropathy. We evaluated the efficacy and safety of imarikiren in patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements This was a randomized, multicenter, placebo-controlled, double-blind, phase 2, dose-finding trial. A total of 415 patients were randomized to imarikiren 5, 20, 40, or 80 mg; placebo; or candesartan cilexetil 8 mg treatment for 12 weeks. The primary end point was change in log-transformed urine albumin-to-creatinine ratio from baseline to the end of treatment analyzed using analysis of covariance and a fixed sequence testing procedure. Secondary efficacy end points included urine albumin-to-creatinine ratio at each assessment point and remission and progression rates. Exploratory efficacy end points included eGFR and sitting BP before dosing. Results Changes in the urine albumin-to-creatinine ratio from baseline to the end of treatment were 16% (placebo), −16% (imarikiren 5 mg), −27% (imarikiren 20 mg), −38% (imarikiren 40 mg), −39% (imarikiren 80 mg), and −31% (candesartan cilexetil 8 mg). Urine albumin-to-creatinine ratio reductions from baseline were statistically significant in all imarikiren groups versus placebo (P<0.001 each) as well as for candesartan cilexetil 8 mg versus placebo (P<0.001). Remission rates (urine albumin-to-creatinine ratio <30 mg/g creatinine and decreased ≥30% from baseline) were higher in all imarikiren groups versus the placebo group. Incidence of adverse events was higher in the imarikiren 80-mg group (52%) versus placebo (42%) and candesartan cilexetil (43%) groups. Incidence of adverse events for the other imarikiren groups ranged from 33% to 42%. Adverse events were mild or moderate in severity. All imarikiren doses were well tolerated. Conclusions Imarikiren resulted in a dose-dependent improvement in albuminuria compared with placebo, and it was well tolerated in patients with type 2 diabetes mellitus and microalbuminuria." @default.
• W2913335890 created "2019-02-21" @default.
• W2913335890 creator A5017301749 @default.
• W2913335890 creator A5020434351 @default.
• W2913335890 creator A5044109406 @default.
• W2913335890 creator A5052304449 @default.
• W2913335890 creator A5052567198 @default.
• W2913335890 creator A5066495888 @default.
• W2913335890 creator A5076069132 @default.
• W2913335890 date "2019-02-12" @default.
• W2913335890 modified "2023-09-25" @default.
• W2913335890 title "Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria" @default.
• W2913335890 cites W1972358173 @default.
• W2913335890 cites W2027087508 @default.
• W2913335890 cites W2034269429 @default.
• W2913335890 cites W2044999311 @default.
• W2913335890 cites W2054393454 @default.
• W2913335890 cites W2054630908 @default.
• W2913335890 cites W2054829090 @default.
• W2913335890 cites W2070066071 @default.
• W2913335890 cites W2084048646 @default.
• W2913335890 cites W2119248404 @default.
• W2913335890 cites W2124475604 @default.
• W2913335890 cites W2138862624 @default.
• W2913335890 cites W2152189242 @default.
• W2913335890 cites W2152798629 @default.
• W2913335890 cites W2154128257 @default.
• W2913335890 cites W2162368776 @default.
• W2913335890 cites W2169855498 @default.
• W2913335890 cites W2218839371 @default.
• W2913335890 cites W2520833569 @default.
• W2913335890 cites W2757385123 @default.
• W2913335890 cites W2790560122 @default.
• W2913335890 cites W2799768029 @default.
• W2913335890 cites W2806504080 @default.
• W2913335890 doi "https://doi.org/10.2215/cjn.07720618" @default.
• W2913335890 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6419291" @default.
• W2913335890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30755452" @default.
• W2913335890 hasPublicationYear "2019" @default.
• W2913335890 type Work @default.
• W2913335890 sameAs 2913335890 @default.
• W2913335890 citedByCount "3" @default.
• W2913335890 countsByYear W29133358902021 @default.
• W2913335890 countsByYear W29133358902022 @default.
• W2913335890 crossrefType "journal-article" @default.
• W2913335890 hasAuthorship W2913335890A5017301749 @default.
• W2913335890 hasAuthorship W2913335890A5020434351 @default.
• W2913335890 hasAuthorship W2913335890A5044109406 @default.
• W2913335890 hasAuthorship W2913335890A5052304449 @default.
• W2913335890 hasAuthorship W2913335890A5052567198 @default.
• W2913335890 hasAuthorship W2913335890A5066495888 @default.
• W2913335890 hasAuthorship W2913335890A5076069132 @default.
• W2913335890 hasBestOaLocation W29133358901 @default.
• W2913335890 hasConcept C126322002 @default.
• W2913335890 hasConcept C126894567 @default.
• W2913335890 hasConcept C134018914 @default.
• W2913335890 hasConcept C142724271 @default.
• W2913335890 hasConcept C159641895 @default.
• W2913335890 hasConcept C204787440 @default.
• W2913335890 hasConcept C27081682 @default.
• W2913335890 hasConcept C2777180221 @default.
• W2913335890 hasConcept C2779922275 @default.
• W2913335890 hasConcept C2780036600 @default.
• W2913335890 hasConcept C2780091579 @default.
• W2913335890 hasConcept C2780306776 @default.
• W2913335890 hasConcept C2781203188 @default.
• W2913335890 hasConcept C2908929049 @default.
• W2913335890 hasConcept C555293320 @default.
• W2913335890 hasConcept C71924100 @default.
• W2913335890 hasConcept C84393581 @default.
• W2913335890 hasConcept C90924648 @default.
• W2913335890 hasConceptScore W2913335890C126322002 @default.
• W2913335890 hasConceptScore W2913335890C126894567 @default.
• W2913335890 hasConceptScore W2913335890C134018914 @default.
• W2913335890 hasConceptScore W2913335890C142724271 @default.
• W2913335890 hasConceptScore W2913335890C159641895 @default.
• W2913335890 hasConceptScore W2913335890C204787440 @default.
• W2913335890 hasConceptScore W2913335890C27081682 @default.
• W2913335890 hasConceptScore W2913335890C2777180221 @default.
• W2913335890 hasConceptScore W2913335890C2779922275 @default.
• W2913335890 hasConceptScore W2913335890C2780036600 @default.
• W2913335890 hasConceptScore W2913335890C2780091579 @default.
• W2913335890 hasConceptScore W2913335890C2780306776 @default.
• W2913335890 hasConceptScore W2913335890C2781203188 @default.
• W2913335890 hasConceptScore W2913335890C2908929049 @default.
• W2913335890 hasConceptScore W2913335890C555293320 @default.
• W2913335890 hasConceptScore W2913335890C71924100 @default.
• W2913335890 hasConceptScore W2913335890C84393581 @default.
• W2913335890 hasConceptScore W2913335890C90924648 @default.
• W2913335890 hasIssue "3" @default.
• W2913335890 hasLocation W29133358901 @default.
• W2913335890 hasLocation W29133358902 @default.
• W2913335890 hasLocation W29133358903 @default.
• W2913335890 hasLocation W29133358904 @default.
• W2913335890 hasOpenAccess W2913335890 @default.
• W2913335890 hasPrimaryLocation W29133358901 @default.
• W2913335890 hasRelatedWork W2046899919 @default.
• W2913335890 hasRelatedWork W2095434474 @default.

• next